EA022434B9 - Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент - Google Patents

Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент

Info

Publication number
EA022434B9
EA022434B9 EA201301114A EA201301114A EA022434B9 EA 022434 B9 EA022434 B9 EA 022434B9 EA 201301114 A EA201301114 A EA 201301114A EA 201301114 A EA201301114 A EA 201301114A EA 022434 B9 EA022434 B9 EA 022434B9
Authority
EA
Eurasian Patent Office
Prior art keywords
phosphoinositide
kinase inhibitor
binding moiety
zinc binding
kinase
Prior art date
Application number
EA201301114A
Other languages
English (en)
Other versions
EA201301114A1 (ru
EA022434B1 (ru
Inventor
Сюн Цай
Хайсяо Чжай
Чэнцзюн Лай
Чангэн Цянь
Жуди Бао
Original Assignee
Кьюрис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кьюрис, Инк. filed Critical Кьюрис, Инк.
Publication of EA201301114A1 publication Critical patent/EA201301114A1/ru
Publication of EA022434B1 publication Critical patent/EA022434B1/ru
Publication of EA022434B9 publication Critical patent/EA022434B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение описывает соединение формулы Iфармацевтические композиции, содержащие такие соединения, и применение таких соединений при лечении заболеваний или нарушений, связанных с фосфоинозитид-3-киназой, таких как рак. Кроме того, изобретение относится к лечению нарушений, связанных с гистоновой деацетилазой, или заболеваний, связанных и с гистоновой деацетилазой и фосфоинозитид-3-киназой.
EA201301114A 2011-04-01 2012-03-30 Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент EA022434B9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161470849P 2011-04-01 2011-04-01
US201161559489P 2011-11-14 2011-11-14
PCT/US2012/031361 WO2012135571A1 (en) 2011-04-01 2012-03-30 Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Publications (3)

Publication Number Publication Date
EA201301114A1 EA201301114A1 (ru) 2014-04-30
EA022434B1 EA022434B1 (ru) 2015-12-30
EA022434B9 true EA022434B9 (ru) 2016-02-29

Family

ID=46931927

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301114A EA022434B9 (ru) 2011-04-01 2012-03-30 Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент

Country Status (30)

Country Link
US (7) US8710219B2 (ru)
EP (2) EP3111938B1 (ru)
JP (3) JP6242331B2 (ru)
KR (2) KR20180108848A (ru)
CN (2) CN103582483B (ru)
AU (1) AU2012236367B2 (ru)
BR (1) BR112013025340B1 (ru)
CA (1) CA2830822C (ru)
CL (1) CL2013002823A1 (ru)
CY (2) CY1117785T1 (ru)
DK (2) DK3111938T3 (ru)
EA (1) EA022434B9 (ru)
ES (2) ES2733128T3 (ru)
HK (1) HK1194969A1 (ru)
HR (2) HRP20160545T1 (ru)
HU (2) HUE045041T2 (ru)
IL (2) IL228588A (ru)
LT (1) LT3111938T (ru)
ME (2) ME02451B (ru)
MX (1) MX340577B (ru)
PE (1) PE20141382A1 (ru)
PL (2) PL2694075T3 (ru)
PT (2) PT2694075T (ru)
RS (2) RS54903B1 (ru)
SG (2) SG193563A1 (ru)
SI (2) SI3111938T1 (ru)
SM (1) SMT201600179B (ru)
TW (1) TWI571469B (ru)
WO (1) WO2012135571A1 (ru)
ZA (2) ZA201307082B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2385832T3 (en) 2009-01-08 2015-09-21 Curis Inc Phosphoinositid-3-kinase-inhibitorer med en zink-bindingsdel
SI3111938T1 (sl) 2011-04-01 2019-08-30 Curis, Inc. Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
KR20140090678A (ko) 2011-11-14 2014-07-17 세파론, 인코포레이티드 AXL 및 c-MET 키나제 억제제로서의 우라실 유도체
CN104725301A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种1,2-二氢吡啶-2-酮衍生物的制备方法
JP6518833B2 (ja) * 2015-04-21 2019-05-22 ▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司Ｇｕｉｚｈｏｕ Ｂａｉｌｉｎｇ Ｇｒｏｕｐ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． プリニル−ｎ−ヒドロキシルピリミジンホルムアミド誘導体、並びにその調製方法および使用
AU2017301012B2 (en) * 2016-07-19 2020-07-09 National Institute Of Plant Genome Research Novel protein against fungal pathogens
AU2017355385A1 (en) * 2016-11-02 2019-05-30 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
WO2023212574A1 (en) * 2022-04-26 2023-11-02 Olivia Szu Hsieh Lee Nakaya Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222343A1 (en) * 2009-01-08 2010-09-02 Xiong Cai Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1277738B1 (en) 2000-04-27 2011-03-30 Astellas Pharma Inc. Condensed heteroaryl derivatives
BR0307575A (pt) 2002-03-13 2004-12-21 Janssen Pharmaceutica Nv Derivados de sulfonila como inibidores de histona desacetilase
CN100519527C (zh) 2002-03-13 2009-07-29 詹森药业有限公司 组织蛋白去乙酰酶抑制剂
DE60321548D1 (de) 2002-03-13 2008-07-24 Janssen Pharmaceutica Nv Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
AU2003209727B2 (en) 2002-03-13 2008-10-16 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2004207706B2 (en) 2003-01-29 2010-03-04 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
EP1745022B1 (en) * 2004-04-05 2014-08-13 Aton Pharma, Inc. Histone deacetylase inhibitor prodrugs
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
JP4862654B2 (ja) 2004-10-08 2012-01-25 アステラス製薬株式会社 芳香環縮合ピリミジン誘導体
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EP2522395A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
AU2006248938B2 (en) 2005-05-18 2011-09-29 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
DK1979328T3 (da) 2006-01-19 2013-03-25 Janssen Pharmaceutica Nv Pyridin- og pyrimidinderivater i deres egenskab af histondeacetylasehæmmere
EP1981871B1 (en) 2006-01-19 2011-12-28 Janssen Pharmaceutica N.V. Heterocyclylalkyl derivatives as novel inhibitors of histone deacetylase
EP1979326B1 (en) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007243457B2 (en) * 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
ATE471940T1 (de) 2006-04-26 2010-07-15 Hoffmann La Roche Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2008033743A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety
US20080161320A1 (en) 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
JP5563300B2 (ja) 2006-09-11 2014-07-30 キュリス，インコーポレイテッド 亜鉛結合部分を含むチロシンキナーゼインヒビター
BRPI0715016A2 (pt) 2006-09-11 2013-05-28 Curis Inc composiÇço, composiÇço farmacÊutica, mÉtodo para tratar uma doenÇa ou distérbio relacionada com tirosina quinase de egfr em um individuo necessitando o mesmo, mÉtodo para tratar uma doenÇa mediada por hdac e mÉtodo para tratar doenÇas medidas tanto por tirosina quinase de egfr quanto hdac
KR20090077914A (ko) 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
CA2667826C (en) 2006-10-28 2013-10-08 Methylgene Inc. Inhibitors of histone deacetylase
JP5284977B2 (ja) * 2006-12-07 2013-09-11 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
BRPI0717907A2 (pt) 2006-12-07 2013-11-05 Genentech Inc "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit"
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
CN101674833A (zh) 2007-03-20 2010-03-17 柯瑞斯公司 含有锌结合半族的Raf激酶抑制剂
TW200922590A (en) 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
WO2009036020A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Mek inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
BRPI0816769A2 (pt) * 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009058895A1 (en) 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
WO2009086012A1 (en) 2007-12-20 2009-07-09 Curis, Inc. Aurora inhibitors containing a zinc binding moiety
JP2011525535A (ja) 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
WO2009155659A1 (en) 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
US8196911B2 (en) 2008-10-27 2012-06-12 Honda Motor Co., Ltd. Adjustable rate subframe mount
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
CA2753285A1 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
CA2776944A1 (en) 2009-10-12 2011-05-12 F. Hoffmann-La Roche Ag Combinations of a pi3k inhibitor and a mek inhibitor
CN102970868A (zh) * 2010-04-16 2013-03-13 柯瑞斯公司 具有k-ras突变的癌症的治疗
SI3111938T1 (sl) * 2011-04-01 2019-08-30 Curis, Inc. Fosfoinozitid 3-kinazni inhibitor z delom, ki veže cink
US20130102595A1 (en) 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
CA2843595C (en) 2011-08-01 2022-10-18 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN107735104B (zh) 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
AU2017355385A1 (en) * 2016-11-02 2019-05-30 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100222343A1 (en) * 2009-01-08 2010-09-02 Xiong Cai Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Also Published As

Publication number Publication date
US20200215039A1 (en) 2020-07-09
US10111864B2 (en) 2018-10-30
PL3111938T3 (pl) 2019-09-30
US11135205B2 (en) 2021-10-05
US20160185796A1 (en) 2016-06-30
RS54903B1 (sr) 2016-10-31
JP6275784B2 (ja) 2018-02-07
JP6242331B2 (ja) 2017-12-06
ES2733128T3 (es) 2019-11-27
EP3111938A1 (en) 2017-01-04
IL228588A0 (en) 2013-12-31
HK1194969A1 (zh) 2014-10-31
US9249156B2 (en) 2016-02-02
CY1121825T1 (el) 2020-07-31
US11654136B2 (en) 2023-05-23
PT2694075T (pt) 2016-07-11
JP2016188255A (ja) 2016-11-04
ME03523B (me) 2020-04-20
CN103582483B (zh) 2016-02-17
JP2018052987A (ja) 2018-04-05
DK3111938T3 (da) 2019-07-01
KR101902325B1 (ko) 2018-09-28
JP2014509653A (ja) 2014-04-21
SI2694075T1 (sl) 2016-07-29
HRP20160545T1 (hr) 2016-06-17
CA2830822A1 (en) 2012-10-04
US10543197B2 (en) 2020-01-28
SG10201602569RA (en) 2016-05-30
IL228588A (en) 2016-11-30
ES2577982T3 (es) 2016-07-19
CN105461736B (zh) 2018-06-12
HRP20191091T1 (hr) 2019-09-20
TWI571469B (zh) 2017-02-21
LT3111938T (lt) 2019-06-25
NZ615586A (en) 2015-02-27
US20140243330A1 (en) 2014-08-28
BR112013025340B1 (pt) 2021-12-21
CA2830822C (en) 2018-10-02
KR20180108848A (ko) 2018-10-04
US20190091211A1 (en) 2019-03-28
IL248597B (en) 2018-04-30
PE20141382A1 (es) 2014-11-04
NZ705039A (en) 2016-03-31
ZA201406167B (en) 2015-03-25
EA201301114A1 (ru) 2014-04-30
RS59219B1 (sr) 2019-10-31
EA022434B1 (ru) 2015-12-30
US8710219B2 (en) 2014-04-29
PL2694075T3 (pl) 2016-09-30
MX340577B (es) 2016-07-13
EP2694075A4 (en) 2014-10-01
CN105461736A (zh) 2016-04-06
CN103582483A (zh) 2014-02-12
DK2694075T3 (en) 2016-08-01
AU2012236367B2 (en) 2014-10-09
MX2013011132A (es) 2014-03-12
US20220168284A1 (en) 2022-06-02
ZA201307082B (en) 2015-04-29
US20130090335A1 (en) 2013-04-11
IL248597A0 (en) 2016-12-29
SI3111938T1 (sl) 2019-08-30
ME02451B (me) 2016-09-20
KR20140023333A (ko) 2014-02-26
SG193563A1 (en) 2013-11-29
EP2694075A1 (en) 2014-02-12
TW201247678A (en) 2012-12-01
US20170304279A1 (en) 2017-10-26
SMT201600179B (it) 2016-08-31
WO2012135571A1 (en) 2012-10-04
AU2012236367A1 (en) 2013-04-18
EP3111938B1 (en) 2019-05-08
HUE028910T2 (en) 2017-01-30
HUE045041T2 (hu) 2019-12-30
CY1117785T1 (el) 2017-05-17
BR112013025340A2 (pt) 2016-12-13
EP2694075B1 (en) 2016-04-27
CL2013002823A1 (es) 2014-04-11
US9657032B2 (en) 2017-05-23
PT3111938T (pt) 2019-07-10

Similar Documents

Publication Publication Date Title
EA022434B9 (ru) Ингибитор фосфоинозитид-3-киназы, содержащий цинксвязывающий фрагмент
MD20150043A2 (ru) Ингибиторы гистон деметилаз
TN2011000053A1 (en) Organic compounds
IN2014DN05772A (ru)
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
IN2014MN00988A (ru)
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
IN2014MN01183A (ru)
PH12014501718A1 (en) Novel therapeutic agents
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
PH12016500225A1 (en) Novel quinoline-substituted compound
IN2012DN00692A (ru)
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
MX2012012530A (es) Derivados de n1-sulfonil-5-fluorpirimidinona.
UY31770A1 (es) Inhibidores de catepsina c
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX340870B (es) Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
WO2012061754A3 (en) Compounds and methods for treating autoimmune diseases
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
MX2012001620A (es) Derivados de n1-acil-5-fluoropirimidinona.
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
BR112012024586A2 (pt) compostos de purina
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent